Perinatal nicotine exposure downregulated angiotensin II type 2 receptor (AT 2 R) in the developing brain and increased brain vulnerability to hypoxic-ischemic injury in male neonatal rats. We tested the hypothesis that sitespecific CpG methylation at AT 2 R gene promoter contributes to the increased vulnerability of brain injury in the neonate. Nicotine was administered to pregnant rats from day 4 of gestation to day 10 after birth. Brain hypoxicischemic injury was induced in day 10 male pups. CpG methylation at AT 2 R promoter was determined in the brain by quantitative methylation-specific PCR. Nicotine exposure significantly increased the methylation of a single CpG −52 locus near the TATA-box at AT 2 R promoter. Electrophoretic mobility shift assay indicated that the methylation of CpG −52 significantly decreased the binding affinity of TATA-binding protein (TBP). Chromatin immunoprecipitation assay further demonstrated an increase in the binding of a methyl-binding protein and a decrease in TBP binding to AT 2 R promoter in vivo in neonatal brains of nicotine-treated animals. This resulted in AT 2 R gene repression in the brain. Intracerebroventricular administration of a demethylating agent 5-aza-2′-deoxycytidine abrogated the enhanced methylation of CpG −52 , rescued the TBP binding, and restored AT 2 R gene expression. Of importance, 5-aza-2′-deoxycytidine reversed the nicotine-increased vulnerability of brain hypoxic-ischemic injury in the neonate. The finding provides mechanistic evidence of increased promoter methylation and resultant AT 2 R gene repression in the developing brain linking perinatal stress and a pathophysiological consequence of heightened vulnerability of brain hypoxic-ischemic encephalopathy in the neonate.
Introduction
Hypoxic-ischemic encephalopathy (HIE) is the most common cause of newborn brain damage due to systemic asphyxia, which may occur prior, during or after birth. HIE causes severe mortality and longlasting morbidity including cerebral palsy, seizure, and cognitive retardation in infants and children (Ferrieo, 2004; Verklan, 2009) . Emerging evidence suggests that aberrant brain development due to fetal stress may underpin the pathogenesis of HIE (Jensen, 2006) . Maternal smoking is the single most widespread perinatal insult in the world and it has been associated with adverse pregnancy outcomes for mother, fetus and the newborn. Recent studies have provided evidence linking perinatal nicotine exposure and the increased incidence of neurodevelopmental disorders, neurobehavioral deficits, impaired cognitive performance, and increased risk of affective disorders later in life (Pauly and Slotkin, 2008; Wickstrom, 2007) . Indeed, our recent study in a rat model has demonstrated that perinatal nicotine exposure suppresses angiotensin II type 2 receptor (AT 2 R) expression in the developing brain, resulting in an increase in the vulnerability of HIE brain injury in a sex-dependent manner in male neonates (Li et al., 2012) .
The mechanisms underlying perinatal nicotine-mediated AT 2 R gene repression in the developing brain remain elusive. Recent studies suggested that CpG methylation in non-CpG island, sequence-specific transcription factor binding sites played an important role in epigenetic modification of gene expression patterns in the developing fetus in response to perinatal stress (Lawrence et al., 2011; Meyer et al., 2009; Patterson et al., 2010; Xiong et al., 2012) . DNA methylation is a chief mechanism for epigenetic modification of gene expression patterns and occurs at cytosine in the CpG dinucleotide sequence (Jaenisch and Bird, 2003; Jones and Takai, 2001; Reik and Dean, 2001) . Methylation in promoter regions is generally associated with the repression of transcription, leading to a long-term shutdown of the associated genes. Methylation of CpG islands in gene promoter regions alters chromatin structure and transcription. Similarly, methylation of a single CpG dinucleotide at sequence-specific transcription factor binding sites may repress gene expression through changes in the binding affinity of transcription factors by altering the major groove structure of DNA to which Neurobiology of Disease 60 (2013) 32-38 
